You are here
Delegate-only final decisions and reasons: NCEs, September 2019
Scheduling of chemicals and poisons
Final decisions on matters not referred to an expert advisory committee
1. New Chemical Entities - medicines for human therapeutic use
Delegate's final decision
The delegate's final decision under regulation 42ZCZU of the Therapeutic Goods Regulations 1990 is to include lorlatinib in Schedule 4 of the Poisons Standard as follows:
Schedule 4 - New Entry
Index - New Entry
1 October 2019
The matters under subsection 52E(1) of the Therapeutic Goods Act 1989 considered relevant by the delegate for the decision include:
- the risks and benefits of the use of a substance:
- The risks and benefits of this medicine require medical diagnosis and ongoing clinical review and monitoring by medical practitioners with expertise in the condition.
- the purposes for which a substance is to be used and the extent of use of a substance:
- Medical diagnosis and ongoing clinical review and monitoring are essential for the appropriate use of this medicine.
- the toxicity of a substance:
- The toxicity of this substance requires ongoing medical review and monitoring.
- the dosage, formulation, labelling, packaging and presentation of a substance:
- the potential for abuse of a substance:
- any other matters that the Secretary considers necessary to protect public health:
The delegate of the Secretary proposed to amend the Poisons Standard with respect to lorlatinib, a new chemical entity (NCE) for a human therapeutic medicine.
Lorlatinib is not specifically scheduled and is not captured by any entry in the Poisons Standard.
- Advice on the place in therapy of this NCE;
- Scheduling Policy Framework (SPF 2018); and
- Section 52E(1) of the Therapeutic Goods Act 1989 in particular: (a) the risks and benefits of the use of a substance; (b) the purposes for which a substance is to be used and the extent of use of a substance; and (c) the toxicity of a substance.